- Home
- EXFY vs IPHA Comparison
EXFY vs IPHA Comparison
Compare EXFY & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXFY | IPHA |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.4M | 174.2M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EXFY | IPHA |
|---|---|---|
| Price | $1.54 | $1.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.75 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 469.9K | 22.0K |
| Earning Date | 11-06-2025 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $143,907,000.00 | $14,839,695.00 |
| Revenue This Year | $4.42 | $22.29 |
| Revenue Next Year | $0.58 | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.71 | N/A |
| 52 Week Low | $1.33 | $1.60 |
| 52 Week High | $4.00 | $2.67 |
Technical Indicators
Market Signals| Indicator | EXFY | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 46.92 | 41.57 |
| Support Level | $1.42 | $1.80 |
| Resistance Level | $1.69 | $1.94 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 43.40 | 19.23 |
Price Performance
Historical ComparisonAbout EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.